Daehan NupharmLtd Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Wonseok Lee
Chief executive officer
₩513.5m
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
Solid Earnings May Not Tell The Whole Story For Daehan NupharmLtd (KOSDAQ:054670)
Nov 20
Daehan New Pharm Co., Ltd.'s (KOSDAQ:054670) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 10What Type Of Shareholders Own The Most Number of Daehan New Pharm Co., Ltd. (KOSDAQ:054670) Shares?
Feb 17Here's Why Daehan New Pharm (KOSDAQ:054670) Can Manage Its Debt Responsibly
Jan 21
If You Had Bought Daehan New Pharm's (KOSDAQ:054670) Shares Five Years Ago You Would Be Down 25%
Dec 31Is Daehan New Pharm Co., Ltd.'s(KOSDAQ:054670) Recent Stock Performance Tethered To Its Strong Fundamentals?
Dec 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | ₩11b |
| Jun 30 2025 | n/a | n/a | ₩10b |
| Mar 31 2025 | n/a | n/a | ₩13b |
| Dec 31 2024 | ₩513m | ₩513m | ₩15b |
Compensation vs Market: Wonseok's total compensation ($USD351.22K) is below average for companies of similar size in the KR market ($USD532.68K).
Compensation vs Earnings: Insufficient data to compare Wonseok's compensation with company performance.
CEO
Wonseok Lee
Mr. Wonseok Lee is CEO & Executive Director of Daehan Nupharm Co.,Ltd. (formerly known as Daehan New Pharm Co., Ltd.) Mr. Lee was a Director at Leaders Technology Investment Co.,Ltd from June 28, 2018 to J...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/27 22:14 |
| End of Day Share Price | 2025/11/27 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daehan Nupharm Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.